UniProt Q96RR4 · PDB · AlphaFold · Substrate: MBP + Ca-CaM · Clone: full-lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Midostaurin | 95.6% | 4.4% | 78.64 | 0.500 |
| 2 | Brigatinib | 95.1% | 4.9% | 82.96 | 0.513 |
| 3 | Alectinib | 93.3% | 6.7% | 95.49 | 0.651 |
| 4 | Ceritinib | 92.7% | 7.3% | 95.44 | 0.618 |
| 5 | Ponatinib | 90.3% | 9.7% | 78.23 | 0.534 |
| 6 | Pacritinib | 85.8% | 14.2% | 88.64 | 0.452 |
| 7 | Abemaciclib | 84.8% | 15.2% | 91.48 | 0.563 |
| 8 | Lorlatinib | 79.2% | 20.8% | 97.24 | 0.694 |
| 9 | Gilteritinib | 76.9% | 23.1% | 88.97 | 0.506 |
| 10 | Bosutinib | 69.2% | 30.8% | 87.22 | 0.555 |
| 11 | Entrectinib | 66.7% | 33.3% | 93.69 | 0.671 |
| 12 | Osimertinib | 65.4% | 34.6% | 97.24 | 0.733 |
| 13 | Defactinib | 58.7% | 41.3% | 92.68 | 0.450 |
| 14 | Axitinib | 56.0% | 44.0% | 93.23 | 0.688 |
| 15 | Crizotinib | 55.1% | 44.9% | 91.39 | 0.581 |
| 16 | Nintedanib | 52.1% | 47.9% | 90.23 | 0.608 |
| 17 | Repotrectinib | 50.9% | 49.1% | 84.21 | 0.608 |
| 18 | Avapritinib | 48.3% | 51.7% | 97.73 | 0.644 |
| 19 | Fostamatinib | 46.3% | 53.7% | 96.74 | 0.613 |
| 20 | Afatinib | 41.1% | 58.9% | 98.50 | 0.709 |
Paralog block
CAMKK1, CAMKK2
EMT expression
- Mesenchymal log2(TPM+1): 4.02
- Epithelial log2(TPM+1): 4.15
- Fold change: -0.13
- Status: No significant change
High-confidence drugs
- Ceritinib — inh 92.7% · KISS 38.39
- Alectinib — inh 93.3% · KISS 35.27
- Lorlatinib — inh 79.2% · KISS 27.22
Selectivity landscape vs inhibition on CAMKK2
Each point is one of the 92 approved drugs; color = inhibition % on CAMKK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…